P2P, or not P2P, that is the question
As the 16 January, 2015 deadline for responding to the controversial P2P draft report draws near, and in the interests of balance and representing the whole community, Phoenix Rising presents two differing views on how to react. Today, Clark Ellis flags up important content to...
Discuss the article on the Forums.

Anyone in the Pridgen/Duffy study? Positive results emerging

Discussion in 'Active Clinical Studies' started by maryb, Mar 19, 2014.

  1. alex3619

    alex3619 Senior Member

    Messages:
    10,165
    Likes:
    21,672
    Logan, Queensland, Australia
    What is the bet he first gave the reporter a complex technical answer, and then the reporter asked him to dumb it down?
     
  2. SOC

    SOC Senior Member

    Messages:
    7,800
    Likes:
    16,212
    :lol: I'll bet you're right!
     
    NK17 likes this.
  3. heapsreal

    heapsreal iherb 10% discount code OPA989,

    Messages:
    8,571
    Likes:
    7,258
    australia (brisbane)
    I guess if they said nsaids reduce tnf alpha, most docs wouldnt understand it??
     
    NK17 and ahimsa like this.
  4. CFS_for_19_years

    CFS_for_19_years คภภเє ɠรค๓թєl

    Messages:
    868
    Likes:
    1,415
    USA
    Reporter: "Can we dumb it down to the level of a Dr. Oz show?"

    (I'm not hating Dr. Oz, it just takes soooo long on that show for him to make one stupid point.)
     
    heapsreal, barbc56 and Sushi like this.
  5. Jon_Tradicionali

    Jon_Tradicionali Alone & Wandering

    Messages:
    268
    Likes:
    262
    Zogor-Ndreaj, Shkodër, Albania
    Study on ACV resistant strains of HSV.
    It agrees that a combination of drugs would be required to be effective against HSV:

    ------------------------------------------------------------------------------------------------------------
    Herpes simplex virus drug-resistance: new mutations and insights.
    Authors
    Andrei G, et al. Show all
    Journal
    Curr Opin Infect Dis. 2013 Dec;26(6):551-60. doi: 10.1097/QCO.0000000000000015.

    Affiliation
    Abstract

    PURPOSE OF REVIEW: Acyclovir (ACV) is the first-line treatment for the management of herpes simplex virus 1 (HSV-1) and 2 (HSV-2) diseases. Long-term administration of the drug for the treatment of chronic infections in the immunocompromised host can lead to the development of ACV-resistance. This review provides an update of the mutations linked to drug-resistance and issues to be considered in the management of HSV infections refractory to antiviral therapy.

    RECENT FINDINGS: Recent data have shown that HSV drug-resistance should be taken into account not only in immunocompromised individuals but also in immunocompetent persons when HSV infections involve 'immune-privileged sites'. Thus, drug-resistance typing is recommended in cases of ACV unresponsive herpetic keratitis and herpes simplex encephalitis. Several issues regarding HSV drug-resistance were highlighted by recent studies. Phenotypic and genotypic antiviral resistance may vary not only from different compartments but also over time, highlighting the importance of characterizing longitudinal HSV isolates from all sites. Combination therapy should be considered when viruses with distinct phenotype/genotype are identified at one or at distinct body sites.

    SUMMARY: Surveillance of HSV drug-resistance is highly recommended in immunocompromised patients and in immunocompetent individuals with infections implicating 'immune-privileged sites' to rationally adapt antiviral treatment.
    ------------------------------------------------------------------------------------------------------------

    http://www.ncbi.nlm.nih.gov/m/pubmed/24152761/?i=10&from=herpes chronic immune
     
    Valentijn likes this.
  6. Rrrr

    Rrrr Senior Member

    Messages:
    1,458
    Likes:
    439
  7. Rrrr

    Rrrr Senior Member

    Messages:
    1,458
    Likes:
    439
    the thing is, he started as a surgeon, not a researcher.
     
  8. Has anyone found if the results of this have come out yet? People were saying 2 weeks about 6 weeks ago, I'm very curious to see what they found.
     
  9. ph_ph

    ph_ph

    Messages:
    4
    Likes:
    4
    Some where I found it mentioned that the Phase 2 trail results will be shared in mid november. Also read that there will be a big press conference prior to that.
     
  10. knackers323

    knackers323 Senior Member

    Messages:
    1,003
    Likes:
    215
    Did they give a reason why this info wasn't released back in March/April when it was meant to be?
     
  11. ph_ph

    ph_ph

    Messages:
    4
    Likes:
    4
    nope, I did not see any reason for why it was delayed.
     
  12. ph_ph

    ph_ph

    Messages:
    4
    Likes:
    4
    It appears the november press release will be much more than just the trail results. There might also be more insight into the cause and other factors of the disease.
     
    RL_sparky and alex3619 like this.
  13. alex3619

    alex3619 Senior Member

    Messages:
    10,165
    Likes:
    21,672
    Logan, Queensland, Australia
    Can you say why you think this?
     
  14. ph_ph

    ph_ph

    Messages:
    4
    Likes:
    4
    One of my friend is getting treated by him .. he shared this info.
     
    shannah and alex3619 like this.
  15. Wally

    Wally Senior Member

    Messages:
    579
    Likes:
    1,256
    Interview with Carol Duffy re drug treatment for HSV-1 with Famciclivor/Celebrex (article dated 10/30/2014).

    http://www.as.ua.edu/home/professor-surgeon-team-headed-to-third-phase-clinical-trials/
    ...
    "The fact that the two drugs worked better together was no surprise to Duffy. Previous research had shown that a particular family of herpes viruses increases the production of COX-2, an enzyme found in most cells whose levels rise during periods of inflammation. Celebrex, a COX-2 inhibitor, stabilizes COX-2 levels and, in doing so, causes herpes virus particles to become unstable.

    “The Famvir inhibits the virus replication, so fewer virus particles are being made, and the Celebrex makes the particles unstable and not infectious,” she said. “Celebrex also inhibits reactivation, so you’re hitting the virus in three different ways.”
    ...
     
  16. Bob

    Bob

    Messages:
    11,321
    Likes:
    27,154
    England (south coast)
    Thanks Wally, that's very interesting.
    Unfortunately it seems that they need to find $50m-$100m for a phase 3 trial now!
     
  17. ggingues

    ggingues $10 gift code at iHerb GAS343 of $40

    Messages:
    4,838
    Likes:
    1,819
    Concord, NH
    Is that all. I have that in my back pocket. LOL

    GG
     
    Bob likes this.
  18. snowathlete

    snowathlete

    Messages:
    2,814
    Likes:
    6,487
    UK
    This is promising. I didn't realise things were as advanced as they are. Raising that sort of cash isn't easy but their is potential there even if it only works out for one or two disease groups. So are they looking specifically at ME/CFS as well or is it just Fibro and IBS?
     
    Bob likes this.
  19. catly

    catly Senior Member

    Messages:
    283
    Likes:
    705
    outside of NYC
    Thanks @Wally for that update. So now we know the anti-viral is Famvir--humm, maybe need to ask my MD to switch my antiviral from Vatrex to Famvir???


    Also, found this intersting from the article "Daniel Clauw, director of chronic pain and fatigue research at the University of Michigan and one of the world’s leading experts on fibromyalgia, joined their scientific advisory board." In light of the fact that he is presenting to the P2P panel in December.
     
    ukxmrv and Bob like this.
  20. Bob

    Bob

    Messages:
    11,321
    Likes:
    27,154
    England (south coast)
    That's what I was wondering. ME/CFS isn't specifically mentioned in the article, and I'm wondering why. Perhaps they are clever and realise that it's so much easier to attract funding if you don't mention ME/CFS? (i.e. it's impossible to get large amounts of funding if you mention ME/CFS!)
     
    Last edited: Nov 8, 2014
    josephine2, snowathlete and ukxmrv like this.

See more popular forum discussions.

Share This Page